Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Zhenshan Zhang

Li Chen

Sung-Sau So

Yun He

Hongying Yun

Paul Gillespie

Fariborz Firooznia

Tai-An Lin

Guozhi Tang

Jason Christopher Wong

Robert Alan Goodnow, Jr

Chungen Liang

Eric Mertz

Xianfeng Lin

Xihan Wu

Zongxing Qiu

Jean-Baptiste Blanc

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein W, X, Y, and R-Rare defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Naphthylacetic acids

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R&#x2014;Rand n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Aminotetrahydroindazoloacetic acids

The present invention provides compounds of formula or pharmaceutically acceptable salts, esters or stereoisomers thereof, wherein Rto R, A and Y have the meanings given herein, as well as methods for making those compounds and their use as medicament, in particular as medicament for the treatment of cancer.

4-amino-N-hydroxy-benzamides for the treatment of cancer

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R-R, A, B, Q, W, and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Bi-aryl aminotetralines

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R-Rand n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Compounds of formula are HDAC inhibitors. These compounds are useful for the treatment of diseases such as cancer in humans or animals.

Ortho aminoamides for the treatment of cancer

Growing community of inventors

Shanghai, China

Zhenshan Zhang